Stuart A.  Randle net worth and biography

Stuart Randle Biography and Net Worth

Director of Teleflex
Mr. Randle is president and chief executive officer of GI Dynamics, Inc., a company in the Boston area focused on developing new therapies for the treatment of Obesity and Diabetes. GI Dynamics is pioneering the approach of noninvasive metabolic control through novel removable devices that modify metabolic pathways. The company has also assembled a world class group of advisors with specialties in bariatric surgery gastroenterology, endocrinology and medical weight loss.

Mr. Randle earned an MBA from The Kellogg Graduate School of Management at Northwestern University and a BS in Mechanical Engineering from Cornell University.

What is Stuart A. Randle's net worth?

The estimated net worth of Stuart A. Randle is at least $6.49 million as of June 8th, 2023. Mr. Randle owns 31,417 shares of Teleflex stock worth more than $6,490,124 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Randle may own. Learn More about Stuart A. Randle's net worth.

How do I contact Stuart A. Randle?

The corporate mailing address for Mr. Randle and other Teleflex executives is 550 E SWEDESFORD RD, WAYNE PA, 19087. Teleflex can also be reached via phone at (610) 225-6800 and via email at [email protected]. Learn More on Stuart A. Randle's contact information.

Has Stuart A. Randle been buying or selling shares of Teleflex?

Stuart A. Randle has not been actively trading shares of Teleflex during the last quarter. Most recently, Stuart A. Randle sold 3,021 shares of the business's stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $245.71, for a transaction totalling $742,289.91. Following the completion of the sale, the director now directly owns 4,847 shares of the company's stock, valued at $1,190,956.37. Learn More on Stuart A. Randle's trading history.

Who are Teleflex's active insiders?

Teleflex's insider roster includes Cameron Hicks (VP), Liam Kelly (CEO), Stephen Klasko (Director), Andrew Krakauer (Director), Thomas Powell (CFO), and Stuart Randle (Director). Learn More on Teleflex's active insiders.

Are insiders buying or selling shares of Teleflex?

During the last year, insiders at the medical technology company sold shares 4 times. They sold a total of 50,630 shares worth more than $12,087,175.55. The most recent insider tranaction occured on March, 5th when VP Cameron P Hicks sold 7,401 shares worth more than $1,665,225.00. Insiders at Teleflex own 1.4% of the company. Learn More about insider trades at Teleflex.

Information on this page was last updated on 3/5/2024.

Stuart A. Randle Insider Trading History at Teleflex

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2023Sell3,021$245.71$742,289.914,847View SEC Filing Icon  
6/7/2022Sell3,014$283.31$853,896.344,320View SEC Filing Icon  
6/4/2021Sell2,384$395.66$943,253.446,762View SEC Filing Icon  
3/11/2019Sell4,000$290.52$1,162,080.007,421View SEC Filing Icon  
11/8/2018Sell2,500$265.23$663,075.007,921View SEC Filing Icon  
6/7/2017Sell2,500$205.67$514,175.007,532View SEC Filing Icon  
6/6/2016Sell797$166.10$132,381.704,592View SEC Filing Icon  
See Full Table

Stuart A. Randle Buying and Selling Activity at Teleflex

This chart shows Stuart A Randle's buying and selling at Teleflex by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teleflex Company Overview

Teleflex logo
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $206.58
Low: $205.46
High: $208.92

50 Day Range

MA: $222.11
Low: $206.56
High: $251.07

2 Week Range

Now: $206.58
Low: $177.63
High: $276.43

Volume

345,088 shs

Average Volume

260,630 shs

Market Capitalization

$9.73 billion

P/E Ratio

27.43

Dividend Yield

0.64%

Beta

1.11